ARAY vs REGN · rev $458.5M vs P/E 14, rev $14.34B
Accuray Incorporated (ARAY) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Accuray Incorporated (ARAY) is a medical devices company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported ARAY revenue for 2025-06-30 was $458.5M. Net income was -$1.6M. Revenue was up 2.7% from 2024-06-30 to 2025-06-30. ARAY currently screens at market cap $140.1M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
ARAY currently screens at market cap $140.1M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the ARAY and REGN stock pages for the full models.
Not investment advice.